Analysts Anticipate Quest Diagnostics Inc (DGX) Will Announce Quarterly Sales of $1.93 Billion

Wall Street analysts expect Quest Diagnostics Inc (NYSE:DGX) to report $1.93 billion in sales for the current quarter, according to Zacks Investment Research. Ten analysts have made estimates for Quest Diagnostics’ earnings. The highest sales estimate is $1.94 billion and the lowest is $1.92 billion. Quest Diagnostics reported sales of $1.86 billion in the same quarter last year, which suggests a positive year over year growth rate of 3.8%. The firm is scheduled to report its next earnings report on Thursday, January 25th.

According to Zacks, analysts expect that Quest Diagnostics will report full-year sales of $1.93 billion for the current fiscal year, with estimates ranging from $7.67 billion to $7.72 billion. For the next financial year, analysts anticipate that the business will report sales of $7.92 billion per share, with estimates ranging from $7.81 billion to $8.02 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Quest Diagnostics.

Quest Diagnostics (NYSE:DGX) last released its quarterly earnings results on Thursday, October 19th. The medical research company reported $1.39 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.35 by $0.04. Quest Diagnostics had a return on equity of 15.53% and a net margin of 8.82%. The business had revenue of $1.93 billion during the quarter, compared to analysts’ expectations of $1.92 billion. During the same period in the previous year, the business posted $1.37 earnings per share. The firm’s revenue for the quarter was up 2.4% compared to the same quarter last year.

A number of research analysts recently issued reports on DGX shares. KeyCorp reaffirmed a “hold” rating on shares of Quest Diagnostics in a report on Friday, October 27th. Wells Fargo & Company cut their price target on Quest Diagnostics from $88.00 to $86.00 and set a “market perform” rating for the company in a report on Friday, October 20th. ValuEngine raised Quest Diagnostics from a “hold” rating to a “buy” rating in a report on Friday, September 1st. Goldman Sachs Group cut Quest Diagnostics from a “conviction-buy” rating to a “buy” rating and cut their price target for the company from $121.00 to $113.00 in a report on Tuesday, October 10th. Finally, Canaccord Genuity lifted their price target on Quest Diagnostics from $100.00 to $105.00 and gave the company a “buy” rating in a report on Thursday, October 26th. One equities research analyst has rated the stock with a sell rating, fifteen have given a hold rating and seven have given a buy rating to the stock. Quest Diagnostics has an average rating of “Hold” and an average target price of $106.28.

Quest Diagnostics (NYSE:DGX) traded down $0.26 during trading on Monday, hitting $98.73. The company had a trading volume of 1,023,733 shares, compared to its average volume of 1,026,439. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.47 and a quick ratio of 1.37. Quest Diagnostics has a fifty-two week low of $90.10 and a fifty-two week high of $112.96. The company has a market capitalization of $13,492.24, a PE ratio of 17.74, a price-to-earnings-growth ratio of 2.06 and a beta of 0.60.

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 24th. Shareholders of record on Tuesday, January 9th will be issued a dividend of $0.45 per share. The ex-dividend date of this dividend is Monday, January 8th. This represents a $1.80 annualized dividend and a yield of 1.82%. Quest Diagnostics’s dividend payout ratio is currently 37.74%.

A number of large investors have recently made changes to their positions in DGX. WFG Advisors LP raised its holdings in Quest Diagnostics by 45.3% during the 2nd quarter. WFG Advisors LP now owns 966 shares of the medical research company’s stock worth $107,000 after purchasing an additional 301 shares during the last quarter. Sun Life Financial INC raised its holdings in Quest Diagnostics by 14,142.9% during the 2nd quarter. Sun Life Financial INC now owns 997 shares of the medical research company’s stock worth $111,000 after purchasing an additional 990 shares during the last quarter. Parallel Advisors LLC grew its position in shares of Quest Diagnostics by 0.9% during the 2nd quarter. Parallel Advisors LLC now owns 1,291 shares of the medical research company’s stock worth $140,000 after buying an additional 12 shares during the period. Acrospire Investment Management LLC grew its position in shares of Quest Diagnostics by 300.0% during the 2nd quarter. Acrospire Investment Management LLC now owns 1,600 shares of the medical research company’s stock worth $178,000 after buying an additional 1,200 shares during the period. Finally, Cubist Systematic Strategies LLC acquired a new position in shares of Quest Diagnostics during the 2nd quarter worth about $180,000. 89.20% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Analysts Anticipate Quest Diagnostics Inc (DGX) Will Announce Quarterly Sales of $1.93 Billion” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The correct version of this report can be read at https://www.americanbankingnews.com/2017/12/18/analysts-anticipate-quest-diagnostics-inc-dgx-will-announce-quarterly-sales-of-1-93-billion.html.

About Quest Diagnostics

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).

Get a free copy of the Zacks research report on Quest Diagnostics (DGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply